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Overweight and obesity are highly prevalent in developed countries and are also becoming more frequent in the developing
world. Overweight and obese patients have elevated levels of several inﬂammatory markers and this inﬂammatory state might
contribute to their increased vascular risk. We summarize the eﬀects of lifestyle changes, antiobesity agents, and bariatric surgery
on serological inﬂammatory markers in overweight and obese patients. Most studies showed a decrease in inﬂammation with all
3 interventions. However, it remains to be established whether the decrease in inﬂammatory markers induced by lifestyle changes
or (where indicated) with antiobesity agents or bariatric surgery will translate into reduced vascular morbidity and mortality in
overweight and obese patients.
1.Introduction
Overweight and obesity are highly prevalent in developed
countries [1]. Approximately one third of the US population
is obese and two thirds are overweight [1]. The prevalence
of obesity is also increasing in developing countries [2]. This
epidemic of overweight and obesity has major implications,
since both overweight and obesity are independently associ-
ated with increased mortality [3–5].
Adipose tissue is not metabolically inert but synthesizes
and secretes proinﬂammatory mediators, including inter-
leukin 6 (IL-6) [6–9], tumor necrosis factor α (TNFα)[ 7,
10, 11], IL-8 [7], and monocyte chemoattractant [protein
1] (MCP-1) [12, 13]. Several studies reported that high
sensitivityC-reactiveproteinlevelsareelevatedinoverweight
and obese patients [14–26]. Compared with lean subjects,
overweight and obese patients also have higher levels of IL-
6[ 9, 19, 24, 26–28], TNFα [24, 26–30], MCP-1 [27], as well
as of other markers of inﬂammation, including IL-8 [31, 32],
IL-18 [33], soluble TNF receptor-2 (sTNFR2) [27, 34, 35],
soluble E-selectin [26, 36, 37], soluble intercellular adhesion
molecule-1 (sICAM-1) [18, 26, 27, 34, 36–38], and soluble
vascular cell adhesion molecule-1 (sVCAM-1) [26, 36]. In
obese patients, inﬂammatory markers correlate with visceral
adipose tissue mass [20, 21, 27, 33, 34, 39–41]a n dw i t h
waist circumference, an index of visceral adiposity [17, 21–
23, 27, 32, 35, 39].
The activation of inﬂammation that is present in obe-
sity might contribute to the increased vascular morbidity
and mortality of these patients, since elevated levels of
inﬂammatory markers are associated with increased vascular
risk [42–46]. In this review, we summarize the eﬀects of
lifestyle changes, antiobesity agents, and bariatric surgery on
serological inﬂammatory markers in obese patients.
2. Lifestyle Measures
Lifestyle measures are the cornerstone of the management
of obesity [47]. In randomized controlled studies, diet and2 Mediators of Inﬂammation
exercise reduced the risk of type 2 diabetes mellitus (T2DM)
inoverweightpatientswithimpairedglucosetolerance(IGT)
[48, 49]. In observational studies, weight loss achieved with
lifestyle changes was associated with reduced incidence of
coronary heart disease (CHD) [50] and with lower all-cause
mortality [51].
Several studies evaluated the eﬀects of diet and exercise
alone or in combination on inﬂammatory markers in obese
patients.
2.1. Diet Alone. Several small studies (n = 11–100) assessed
the eﬀects of low-calorie, very low-calorie, low-fat, or
low-carbohydrate diets on inﬂammatory markers in obese
patients (Table 1)[ 20, 22, 28, 52–75]. The duration of the
intervention ranged from 3 weeks to 17 months [20, 22, 28,
52–75]. The majority of studies noted a signiﬁcant decrease
in CRP after weight loss induced by dietary modiﬁcation in
otherwise healthy overweight or obese adults [20, 22, 52,
54, 56–60, 62, 64–68, 70, 72–75], in obese patients with
the metabolic syndrome [69], in overweight patients with
raised triglycerides (TG) [55], in severely obese patients [71],
or in obese patients with T2DM [53]. In some studies, the
magnitudeofdecreaseinhsCRPlevelswaslinearlycorrelated
to the amount of weight loss [20, 22, 67]. Only few reports
did not record a signiﬁcant fall in hsCRP concentration after
weight loss [28, 63].
Furthermore, several studies compared the eﬀects of
diﬀerent diets on inﬂammatory markers [52–54, 56, 57,
59, 62, 65–68, 70–73]. Heald et al. reported a signiﬁcant
24% decrease in serum hsCRP levels after 3 months of
replacement of high-fat foods with reduced-fat alternatives
[59]. In another study, a carbohydrate restricted diet (CRD)
with daily intake of eggs decreased hsCRP levels compared
with a CRD without eggs, indicating that eggs signiﬁcantly
contribute to the anti-inﬂammatory eﬀects of CRD possibly
due to the antioxidant lutein which is present in eggs
and modulates certain inﬂammatory responses [70]. A
low-glycemic-load diet was also associated with a signiﬁ-
cantly greater improvement in serum hsCRP concentration
compared with a low-fat diet (48 versus 5%) despite
the similar weight loss in both diets [68]. In contrast, a
more recent study reported a greater fall in hsCRP levels
after a high-carbohydrate, low-saturated-fat diet compared
with an isocaloric very-low-carbohydrate, high-saturated-
fat diet, even though the latter group lost more weight
and abdominal fat [62]. However, most studies comparing
diets of diﬀerent composition reported a similar decrease
in hsCRP concentration among groups, suggesting that the
weight loss per se rather than the dietary composition is the
primary determinant of the fall in inﬂammatory markers
during diet [52–54, 56, 57, 65–67, 71–73].
The eﬀect of dietary intervention on other inﬂammatory
markers is more controversial. Some studies reported a
r e d u c t i o ni ns e r u mT N F α levels with diet [31, 72, 74, 76, 77]
whileothershavenot[28,70,75].Similarly,serumIL-6levels
fellafterdiet-inducedweightlossinsome[28,31,72,76],but
not all studies [60, 74]. Regarding the eﬀects of diet on IL-8,
a signiﬁcant reduction [76], increase [31], or no change [70]
has been reported. In addition, caloric restriction did not
aﬀect circulating levels of the anti-inﬂammatory cytokine
IL-10 [78]. However, limited data suggest that diet-induced
weight loss is associated with a proportional reduction in
IL-18 [33]a n dI L - 2 0l e v e l s[ 79]. Weight loss by caloric
restrictionalsoinducessigniﬁcantdecreasesinsICAM-1[36,
52, 55, 61, 62, 72] and sVCAM-1 levels [36, 61, 80]. Only one
study reported no change in sICAM-1 and sVCAM-1 levels
[70] and another study reported an increase in sVCAM-1
levels [62].
The conﬂicting results mentioned above could be
attributed to the diﬀerences in baseline characteristics of
the studied population that might inﬂuence inﬂammatory
markers (i.e., age, gender and coexisting diseases), the brief
duration of the intervention, the insuﬃcient sample size, or
the degree of body weight reduction. Overall, the greatest
reductions in serological markers of inﬂammation were
observed in studies where an at least 10% weight loss was
achieved.
Interestingly, recent studies demonstrated that brief peri-
odsofreducedfoodintakecanincreaseresistancetoischemia
reperfusion injury in rodents and modify circulating levels
of pro-inﬂammatory agents in humans [81, 82]. The eﬀects
of short-term interventions on inﬂammation appear to be
mostly due to the calorie restriction and negative energy
balance whereas in long-term interventions weight loss and
adipose mass reduction also contribute to the suppression of
inﬂammation.However,existingstudiesdonotshowamajor
diﬀerence between the eﬀects of short and long terms of
calorierestrictiononthelevelsofinﬂammatorymarkers.The
2 studies that did not report an eﬀect of diet on hsCRP levels
lasted for 3 weeks and 3 months, respectively [28, 63]. In
addition, both short- and long-lasting dietary interventions
(3 weeks to 17 months) induced a reduction in hsCRP levels
in several studies [20, 22, 52–60, 62, 64–75].
2.2. Exercise Alone. A number of small studies (n =
8–199) evaluated the eﬀects of exercise training, resistance
training, or aerobic exercise training for 2–12 months on
inﬂammatory markers (Table 1)[ 35, 83–93]. Some [83–87]
b u tn o ta l l[ 88–90] studies reported a signiﬁcant reduction
in serum hsCRP levels. Interestingly, body weight changed
only slightly in some studies that reported a signiﬁcant fall
in hsCRP levels [83–85]. Limited data exist on the impact
of exercise on other markers of inﬂammation. Serum TFα
levels fell after aerobic exercise training in most [35, 87, 91]
but not all studies [84]. In contrast, serum IL-6 levels did
not change with exercise in most reports [83, 85, 89]a n d
f e l lo n l yi n1s t u d y[ 90]. The concentration of IL-10, an
anti-inﬂammatory cytokine, increased after 6 months of
aerobic exercise in overweight patients with T2DM [84]
and serum IL-18 concentration decreased in the same study
[84], but remained unchanged in another [93]. In addition,
sICAM-1 and sVCAM-1 levels were not aﬀected after one
year of resistance training [85]. In a recent controlled
exercise training intervention, 189 overweight and mildly
obese patients were randomized to 6 months of inactivity
or 1 of 3 types of aerobic exercise training regimens: low-
amount/moderate intensity, low-amount/vigorous intensity,
and high-amount/vigorous intensity [92]. Despite a meanMediators of Inﬂammation 3
Table 1: Eﬀects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inﬂammation in obese patients.
Intervention Marker of inﬂammation Eﬀect Reference
Diet alone
hsCRP ↓ ↓:[ 20, 22, 52–60, 62, 64–
75, 115, 118] or no eﬀect
no eﬀect: [28, 63]
TNFα ↓ ↓:[ 31, 72, 74, 76, 77]
or ↑ ↑:[ 117]
or no eﬀect no eﬀect: [28, 70, 75, 115, 118]
IL-6 ↓ ↓:[ 28, 31, 72, 76, 115]
or no eﬀect no eﬀect: [60, 74]
IL-8 ↓ ↓:[ 76]
or ↑ ↑:[ 31]
or no eﬀect no eﬀect: [70]
IL-10 No eﬀect [78]
IL-18 ↓ [33]
IL-20 ↓ [79]
sICAM-1 ↓ ↓:[ 36, 52, 55, 61, 62, 72]
or no eﬀect no eﬀect: [70]
sVCAM-1 ↓ ↓:[ 36, 61, 80]
or ↑ ↑:[ 62]
or no eﬀect no eﬀect: [70]
Exercise alone
hsCRP ↓ ↓:[ 83–87]
or no eﬀect no eﬀect:
[88–90, 92, 115, 116, 118]
TNFα ↓ ↓:[ 35, 87, 91]
or ↑ ↑:[ 117]
or no eﬀect no eﬀect:
[84, 92, 115, 116, 118]
IL-6 ↓ ↓:[ 90]
or no eﬀect no eﬀect:
[83, 85, 89, 92, 115, 116]
IL-10 ↑ [84]
IL-18 ↓ ↓:[ 84]
or no eﬀect no eﬀect: [93]
sICAM-1 No eﬀect [85]
sVCAM-1 No eﬀect [85]
Combination of diet and exercise
hsCRP
↓ ↓:[ 26, 29, 40, 94–96, 98–
116, 118]
or no eﬀect no eﬀect: [97]
TNFα ↓ ↓:[ 26, 40, 101, 105]
or ↑ ↑:[ 117]
or no eﬀect no eﬀect: [94, 95, 97, 109,
112, 115, 116, 118]
IL-6 ↓ ↓:[ 26, 94, 97, 98, 100–
103, 107, 110–
113, 115, 116] or no eﬀect
no eﬀect: [95, 96, 109]
IL-7 ↓ [111]
IL-8 ↓ [113]
IL-18 ↓ [100–102, 106, 111]
sICAM-1 ↓ [26, 104]
sVCAM-1 ↓ [26]4 Mediators of Inﬂammation
Table 1: Continued.
Intervention Marker of inﬂammation Eﬀect Reference
Orlistat
hsCRP ↓↓ :[ 123–125, 128]
or no eﬀect no eﬀect: [126, 127, 133]
TNFα ↓ [123, 127, 129]
IL-6 ↓↓ :[ 123, 124, 129]
or no eﬀect no eﬀect: [127]
Sibutramine
hsCRP ↓↓ :[ 132, 133, 147]
or no eﬀect no eﬀect: [135]
TNFα ↓ [134]
IL-6 ↓ [134]
IL-10 ↑ [134]
Metformin
hsCRP ↓↓ :[ 139, 141, 144, 146, 147]
or no eﬀect no eﬀect: [140, 142, 145]
TNFα No eﬀect [139, 145]
IL-6 ↓↓ :[ 144]
or no eﬀect no eﬀect: [139, 145]
sICAM-1 ↓↓ :[ 139]
or no eﬀect no eﬀect: [138, 140, 146]
sVCAM-1 ↓ [138–140, 146]
soluble E-selectin ↓↓ :[ 139, 140]
or no eﬀect no eﬀect: [138, 146]
Roux-en-Y gastric bypass
hsCRP ↓ [158–166]
TNFα No eﬀect [166]
sTNFR-2 No eﬀect [166]
IL-6 ↓↓ :[ 160, 162, 163, 165]
or no eﬀect no eﬀect: [166]
IL-18 ↓ [180]
sICAM-1 No eﬀect [166]
sVCAM-1 No eﬀect [166]
soluble E-selectin ↓ [166]
MCP-1 ↓ [180]
Gastric banding
hsCRP ↓↓ :[ 158, 169–175]
or no eﬀect no eﬀect: [176]
TNFα No eﬀect [172, 174]
sTNFR-2 ↓ [167, 180]
IL-6 ↓↓ :[ 171, 172]
or no eﬀect no eﬀect: [174]
IL-18 ↓ [167]
sICAM-1 ↓↓ :[ 37, 171, 182]
or no eﬀect no eﬀect: [176]
sVCAM-1 ↓↓ :[ 176]
or no eﬀect no eﬀect: [181]
soluble E-selectin ↓ [37, 176, 181, 182]
MCP-1 ↓ [167]
Liposuction
hsCRP No eﬀect No eﬀect: [183, 184]
or ↓↓ :[ 185]
TNFα No eﬀect No eﬀect: [183, 184]
or ↓↓ :[ 185]
IL-6 No eﬀect No eﬀect: [183, 184]
or ↓↓ :[ 185]
IL-18 ↓ [185]
hsCRP: high sensitivity C-reactive protein; IL: interleukin; TNFα: tumor necrosis factor α; sICAM-1: soluble intercellular adhesion molecule 1; sVCAM-1:
soluble vascular cell adhesion molecule 1; sTNFR-2: soluble TNF receptor 2.Mediators of Inﬂammation 5
reduction of adipose tissue mass by 9 ± 11% (or 2.5 ±
3.0kg), exercise training did not aﬀect hsCRP, IL-6, or TFα
levels to a signiﬁcant degree [92].
Diﬀerencesinthetype,frequency,intensity,andduration
of exercise, in the amount of achieved weight loss, and/or in
the duration of the study may partly explain the observed
discrepancies in the eﬀects of exercise on markers of inﬂam-
mation. Moreover, the participants were mainly overweight
or mildly obese, with variable baseline characteristics (age,
gender, previous physical activity, all of which might have
inﬂuenced the results). Finally, it has been reported that both
strenuous exercise (which can lead to muscle damage) and
overtraining (which might induce oxidative stress) might act
asaninﬂammatorystimulusandraiseinﬂammatorymarkers
[86].
2.3. Combination of Diet and Exercise. More data are avail-
able on the eﬀects of combining both diet and exercise
on inﬂammatory markers (Table 1)[ 26, 29, 40, 94–114].
All studies (n = 12–190, duration 4 weeks to 2 years)
reported a signiﬁcant decrease in BMI in overweight [94,
111, 112], obese [26, 29, 40, 95–107, 109, 111, 112]a n d
morbidlyobesepatients[110,113,114].Interestingly,hsCRP
levels signiﬁcantly decreased in all but 1 of these studies
[26, 29, 40, 94–96, 98–114]; the remaining study reported
a nonsigniﬁcant fall in hsCRP concentration (P = .71)
[97]. Inaccordancewithdiet-only studies, hsCRP reductions
after diet and exercise correlated positively with changes in
body weight and fat mass [101]. The majority of studies also
showed a signiﬁcant decrease in serum IL-6 concentration
after a multidisciplinary program including diet and exercise
[26, 94, 97, 98, 100–103, 107, 110–113] and only few studies
did not [95, 96, 109]. Furthermore, all studies that evaluated
the eﬀects of caloric restriction and exercise on serum IL-18
levels observed a signiﬁcant decrease [100–102, 106, 111].
Limited data also suggest that diet and increased physical
activity decrease IL-7 [111], IL-8 [113], sICAM-1 [26, 104],
and sVCAM-1 levels [26]. In contrast, the eﬀects of diet
a n de x e r c i s eo ns e r u mT N F α levels were less consistent with
both signiﬁcant decreases [26, 40, 101, 105] and no change
reported [94, 95, 97, 109, 112].
Finally, 4 studies assessed the separate and combined
eﬀects of exercise and diet intervention on several cytokines.
Nicklas et al. reported that an 18-month dietary intervention
resulted in signiﬁcant reductions in hsCRP and IL-6 concen-
trations (but not in TNFα levels) whereas exercise training
had no eﬀect; however, weight loss was observed only in
patients on diet [115]. Patients on both diet and exercise did
not show greater reductions in hsCRP and IL-6 levels than
those on diet alone [115]. In another study, 6 months of diet
plus exercise, but not exercise alone, decreased hsCRP and
IL-6 levels (but not TNFα levels) in obese postmenopausal
women despite a similar weight and fat loss in both groups
[116]. Rokling-Andersen et al. randomly allocated 188
men with vascular risk factors to 4 groups: diet, exercise,
combined diet and exercise, and control [117]. Serum TNFα
levels increased signiﬁcantly in the 3 intervention groups but
the increase was smaller in the combined diet and exercise
group and probably represents a chance ﬁnding [117]. In
another study, 33 obese postmenopausal women with T2DM
were assigned to diet, exercise, or diet and exercise for 14
weeks. Serum hsCRP levels decreased by approximately 15%
with all interventions even though weight loss was observed
only in patients assigned to diet alone or with exercise [118].
In contrast, serum TNFα levels did not change signiﬁcantly
[118].
The conﬂicting eﬀects of the combination of diet and
exercise on inﬂammatory markers are probably due to the
short duration of the majority of the studies, the small
number of participants, or the varying weight loss achieved.
The lack of a decrease in serum TNFα concentration may
be a result of its transient production and short half-life.
Similar to the studies that assessed dietary modiﬁcations
alone, a weight loss of at least 10% resulted in the greatest
improvements in serological markers of inﬂammation in
studies where diet was combined with exercise.
Overall, diet and exercise alone or in combination have
favourable eﬀects on serum inﬂammatory markers. The
inconsistent ﬁndings in some studies may be due to (apart
from the reasons already mentioned) diﬀerences in the
studied population (i.e., overweight, obese, patients with
diabetes), in the baseline concentration of cytokines and
inﬂammatory status of each patient, as well as in the
laboratory methods used for the measurement of cytokines.
3. AntiobesityAgents
Orlistatinducesweightlossbyreducingintestinalfatabsorp-
tion (by up to 30%) by binding to pancreatic lipases and
partiallyinhibitingthehydrolysisofdietaryfat(triglycerides)
into absorbable free fatty acids and monoacylglycerols [119].
Compared with placebo, orlistat reduces body weight by
approximately 2.9kg (95% conﬁdence interval (CI) 2.5–
3.2kg) in studies lasting more than 1 year [120]. In addition,
orlistat lowers low density lipoprotein cholesterol (LDL-C)
levels, reduces blood pressure (BP), and improves glycemic
control in diabetic patients [120, 121]. More importantly,
in XENical in the prevention of Diabetes in Obese Subjects
(XENDOS) study, orlistat reduced the risk of developing
T2DM in obese patients with impaired glucose tolerance
[122].
A limited number of studies evaluated the eﬀects of
orlistat on inﬂammatory markers in obese patients (Table 1).
In some reports, treatment with orlistat for up to 1 year
reduced hsCRP levels [123–125]. However, in other studies
the fall in CRP levels during orlistat treatment did not
reach statistical signiﬁcance [126, 127]. In addition, in a
placebo-controlled study that evaluated the eﬀects of long-
term(3years)treatmentwithorlistat,hsCRPlevelsdecreased
signiﬁcantly only in patients who lost more than 11% of
their body weight [128]. It is of interest to point out that
all 3 studies that reported a decrease in hsCRP levels during
orlistattreatment[123–125]lastedfor6monthsormoreand
hsCRP levels were measured. In contrast, negative studies
evaluated CRP levels, which are less sensitive for evaluating
inﬂammation than hsCRP [126, 127]. Moreover, baseline6 Mediators of Inﬂammation
CRP levels were within the normal range in both negative
studies and this might have limited their statistical power
to show a signiﬁcant decrease in CRP levels [126, 127].
Finally, both negative studies had shorter follow-up than
the studies that reported a decrease in hsCRP levels during
orlistat treatment (3 and 4 months, resp.) and the potential
antiinﬂammatory eﬀect of orlistat might have not become
apparent yet at study completion [123–127].
Ar e d u c t i o ni ns e r u mI L - 6[ 123, 124, 129]a n dT N F α
levels was also reported after treatment with orlistat [123,
127, 129]. Orlistat did not aﬀect serum IL-6 levels only in
one study, which however had a short follow-up as already
mentioned (4 months versus 6 months or more in other
reports) [127]. Interestingly, the decrease in hsCRP and
TNFα in some studies was greater in the diet plus orlistat
group compared with patients who were only on diet even
after correcting for the greater weight loss observed in the
orlistat group [123, 125, 129]. Overall, it appears that 6
months or more of treatment with orlistat and a weight loss
greater than 10% are required for a signiﬁcant reduction in
inﬂammatory markers with this agent.
Sibutraminelowersbodyweightbyincreasingsatietyand
by reducing appetite through the selective inhibition of the
neuronalreuptakeofserotoninandnoradrenalinewithinthe
hypothalamus[130,131].Instudieslastingmorethan1year,
sibutramine reduced body weight by approximately 4.2kg
(95% CI 3.6–4.7kg) compared with placebo [120, 130].
Sibutraminealsolowerstriglyceride(TG)levelsbutincreases
BP and pulse rate [120, 130].
In some studies, sibutramine reduced serum levels of
hsCRP [132, 133], IL-6, and TNFα and increased serum
levels of IL-10 when given for 3–6 months (Table 1)[ 134]. A
weight loss of 6.1–7.1kg (5.4%–6.9%) was observed during
thelatterstudies[133,134]andcorrelatedwiththereduction
in IL-6 levels [134]. In another study, treatment with sibu-
tramine for 6 months did not aﬀect hsCRP levels; however,
the weight loss achieved in this study was substantially
smaller (2.4kg or 2.9%) [135]. Therefore, similarly with
orlistat, weight loss appears to be the major factor that
determines the anti-inﬂammatory eﬀect of sibutramine.
In a nonrandomized, nonblinded comparative study,
only sibutramine reduced hsCRP levels after 6 months
whereas changes in hsCRP levels were nonsigniﬁcant in
patientsgivenorlistat[133].However,weightlosswasgreater
in the sibutramine group compared with the orlistat group
(5.4% versus 2.5%, resp.), suggesting again that the degree
of weight loss correlates with the anti-inﬂammatory action
of these antiobesity agents [133]. Whether orlistat or sibu-
tramineexertsananti-inﬂammatoryactionindependentlyof
weight loss is unclear.
It should emphasized that the Committee for Medicinal
Products for Human Use of the European Medicines
Agency recently concluded that the risks of sibutramine are
greater than its beneﬁts and recommended the suspension
of marketing authorization of this agent across the
European Union (http://www.ema.europa.eu/pdfs/human/
referral/sibutramine/3940810en.pdf; accessed 25/1/2010).
The Food and Drug Administration also stated that
sibutramine is not to be used in patients with a history of
coronary heart disease, stroke or transient ischemic attack,
heart failure, heart arrhythmias, peripheral arterial disease,
or uncontrolled hypertension (http://www.fda.gov/Safety/
MedWatch/SafetyInformation/SafetyAlertsforHumanMedi-
calProducts/ucm198221.htm; accessed 25/1/2010). These
recommendations were based on the results of the
SibutramineCardiovascularOutcomeTrial(SCOUT),which
showed an increased risk of nonfatal cardiovascular events
with sibutramine compared with placebo in patients with
known or high risk for cardiovascular disease (http://www
.ema.europa.eu/pdfs/human/referral/sibutramine/3940810-
en.pdf and http://www.fda.gov/Safety/MedWatch/SafetyIn-
formation/SafetyAlertsforHumanMedicalProducts/ucm-
198221.htm; accessed 25/1/2010).
Metformin enhances insulin sensitivity, lowers hepatic
glucose production, and is a ﬁrst-line treatment for T2DM
[136, 137]. Metformin frequently induces a modest weight
loss in diabetic patients [136]. In 4 studies in patients with
T2DM, treatment with metformin for 3-4 months exerted
conﬂicting eﬀects on serum hsCRP, IL-6, TNFα, sICAM-1,
sVCAM-1, and soluble E-selectin levels (Table 1)[ 138–141].
In one study where metformin was administered only for 1
month, no signiﬁcant change was observed in hsCRP levels
[142]. Metformin is also used in the management of patients
with polycystic ovary syndrome (PCOS), where it has been
shown to ameliorate reproductive abnormalities, restore
ovulation and regular menses, increase pregnancy rates, and
reduce androgen production [143] .I n3s t u d i e si nw o m e n
with PCOS, treatment with metformin for 6 months also
had contradictory eﬀects on hsCRP, IL-6, TNF-α, sICAM-1,
sVCAM-1, and soluble E-selectin levels (Table 1)[ 144–146].
In addition to the unclear eﬀects of metformin on inﬂam-
matory markers, it should be emphasized that metformin is
not currently recommended for the management of obesity.
Moreover, a recent study in nondiabetic obese women
showedthatsibutraminemonotherapyreducedhsCRPlevels
and that adding metformin to sibutramine did not result in
any additional decrease in hsCRP levels [147].
4.BariatricSurgery
Bariatric surgery is classiﬁed in restrictive (laparoscopic
adjustable gastric banding and vertical banded gastroplasty),
malabsorptive (biliopancreatic diversion with or without
duodenal switch), and combination procedures (Roux-en-Y
gastric bypass) [148]. All forms of bariatric surgery result in
loss of more than 50% of excess weight [149]. In addition,
hypertension, T2DM, hyperlipidemia, and obstructive sleep
apnea resolve in the majority of patients who undergo
bariatric surgery [149]. More importantly, bariatric surgery
was associated with reduced all-cause mortality in several
retrospective studies [150–152] and in a prospective study
[153]. Malabsorptive or combination procedures induce
greater weight loss [152, 154–157] and appear to be more
eﬀectiveintheresolutionofobesity-associatedcomorbidities
[149, 157]. However, they are also associated with higher
complication rates compared with restrictive procedures
[149, 151, 154].Mediators of Inﬂammation 7
Several studies reported a reduction in serum hsCRP
levels after Roux-en-Y gastric bypass (Table 1)[ 158–166].
This decrease in hsCRP levels is greater in patients who
lost more weight after surgery [164, 166]. A decline in
hsCRP levels also occurs in patients undergoing gastric
banding (Table 1)[ 158, 167–175] .T h ed e c r e a s ei nh s C R P
levels correlated with the fall in BMI in some of these
studies [172]. Only one study did not report a signiﬁcant
change of hsCRP levels after gastric banding; however, the
decrease in hsCRP levels in this report was signiﬁcant 6
months after surgery (P = .05) and there was a trend for
signiﬁcant decrease also at 12 months (P = .08) [176].
In a recent study, patients who underwent gastric bypass
lost more weight than those who underwent gastric banding
but the fall in hsCRP levels was similar in both groups
[158]. Other less frequently performed bariatric procedures,
such as biliopancreatic diversion [177], laparoscopic sleeve
gastrectomy [178], and gastric partition [179], also result
in a decrease in hsCRP levels that in some cases correlates
with the reduction in BMI [178]. The reduction in hsCRP
levels in almost all studies of all types of bariatric surgery, in
contradiction to the equivocal results of lifestyle changes and
antiobesity agents, further supports the notion that weight
loss per se is the main factor that causes the fall in hsCRP
levels, since bariatric surgery results in substantially greater
weight loss than lifestyle changes or antiobesity agents. The
lack of correlation between weight loss and hsCRP fall might
be attributed to the small number of patients included in
these studies, which limits their statistical power.
Other markers of inﬂammation, including IL-6 [160,
162, 163, 165], IL-18 [180], MCP-1 [180], and soluble E-
selectin [166] also fall after gastric bypass (Table 1). Only
1s m a l ls t u d y( n = 26) did not report signiﬁcant changes
in IL-6, TNFα, sTNFR-2, sICAM-1, and sVCAM-1 levels
following gastric bypass [166]. However, serum hsCRP
levels, which are a more sensitive and speciﬁc marker of
inﬂammation, decreased in this study [166]. Serum levels
of IL-6 [171, 172], IL-18 [167], sTNFR-2 [167, 170], MCP-
1[ 167], soluble E-selectin [37, 176, 181, 182], sICAM-1
[37, 181, 182], and sVCAM-1 levels [176] also fall after
gastric banding (Table 1). The change in soluble E-selectin
and sICAM-1 levels correlated with the reduction in BMI
[37,182].However,IL-6[174],sVCAM-1[181],andsICAM-
1l e v e l s[ 176] did not change signiﬁcantly in other studies.
In addition, serum TNFα levels [172, 174]w e r en o ta ﬀected
by gastric banding. Again, serum hsCRP levels fell in most
studies that did not record a signiﬁcant change in other
inﬂammatory markers [172, 174], suggesting that the latter
might be less sensitive in identifying a clinically signiﬁcant
anti-inﬂammatory eﬀect of bariatric surgery.
In contrast to bariatric surgery, removal of abdominal
subcutaneous fat by liposuction does not appear to reduce
hsCRP, IL-6, or TNFα levels (Table 1)[ 183, 184]. However,
one study reported a reduction in serum hsCRP, IL-6, IL-18,
and TNFα levels after liposuction [185]. In the latter study,
the amount of fat aspirate correlated with the reduction
in TNFα levels [185]. Even though the data on the eﬀect
of liposuction on inﬂammatory markers are limited, the
predominantly negative ﬁndings are concordant with the
concept that visceral adipose tissue is the main factor
inducing the inﬂammatory milieu of obese patients whereas
subcutaneous adipose tissue is less important.
5. Conclusions
Existing evidencesuggests that lifestyle measures, antiobesity
agents, and bariatric surgery reduce serum levels of inﬂam-
matory markers in obese patients. The lack of signiﬁcant
change in some studies appears to be due to small sample
size and/or small weight loss achieved. It appears that the
reduction in inﬂammation is primarily driven by weight
loss [186]. In a recent meta-analysis, a linear relation was
observed between weight loss following lifestyle changes or
bariatric surgery and the fall in hsCRP levels, which declined
by 0.13mg/L for each 1kg of weight loss [186]. What
remains to be established is whether reducing inﬂammatory
markers in obese patients with lifestyle measures or (where
indicated) with bariatric surgery or drugs will translate in
lower vascular risk. In this context, a beneﬁcial eﬀect of
suppressing inﬂammation has been reported during statin
treatment in patients with or without established vascular
disease, even though it was not assessed whether obese
patients beneﬁt more or less [187–189].
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